



Narhex Life Sciences Ltd

Level 24, 44 St George's Terrace
PERTH WA 6000
P: +61-8-6211 5099
F: +61-8-9218 8875
ABN: 51 094 468 318

1 May 2013

Company Announcements Office
Australian Securities Exchange
10th Floor, 20 Bond Street
SYDNEY NSW 2000

Dear Sir

Narhex Life Sciences International Pty Ltd

By way of background, Narhex Life Sciences Ltd ("**NLS**" or the "**Company**") has a 50% shareholding in Narhex Life Sciences International Pty Ltd ("**NLSI**"). The other 50% shareholding is held by Narhex Life Sciences Developments Limited ("**NLSD**"). NLSI holds a 75% interest in the Xi'an Hex Joint Venture, established to develop NLSI's patented HIV inhibitor drugs DG17 and DG43, together with an interest in Cavid AB.

NLS and NLSD signed the NLSI Shareholders Agreement dated 25 June 2010 which provided for an initial contribution of \$500,000 from NLSD (which has been paid). The Agreement then provided for the next payment of \$500,000 to be made by NLS. NLS has now received from NLSI a cash call for \$500,000 in accordance with the Shareholders Agreement.

The Directors of the Company have resolved to not meet the cash call and consequently will lose its interest in NLSI.

The Company has previously announced its intent to move towards acquiring gold and diamond tenements in Liberia (more below) and the decision to discontinue its interest in NLSI is in keeping with that decision.

Resignation of Director

The Board wishes to advise that Mr Ian Reynolds has resigned as a director of the Company. He continues in his roles as a Director of both NLSI and NLSD. A copy of his Appendix 3Z – Final Director's Interest Notice is attached.

Liberian Gold and Diamond Project Update

Further to the Company's announcement released on 28 February 2013, the Board confirms that Golden Saint Australia Limited has agreed to extend the due diligence period until 1 June 2013. A final report on the results of the geological and legal due diligence activities being conducted on the mining tenements in Liberia will be provided during May.

Yours faithfully

Simon Lill
Director

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	NARHEX LIFE SCIENCES LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Mr Ian Reynolds
Date of last notice	27 February 2013
Date that director ceased to be director	30 April 2013

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
Narhex Life Sciences Developments Limited – Mr Reynolds is a director of the entity and has a beneficial interest	40,000,000 fully paid ordinary shares
Tittel Pty Ltd – Mr Reynolds is a director of the entity and has a beneficial interest	41,000 fully paid ordinary shares

Part 3 – Director's interests in contracts

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.